Chimeric TherapeuticsCHMMF -96.67%13 Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 840 Biotechnology companies, Chimeric Therapeutics ranks better than 95.12% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Chimeric Therapeutics's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Chimeric Therapeutics's average Accounts Receivable for the
six
months ended in Dec. 2025 was $1.68 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Chimeric Therapeutics Receivables Turnover Related Terms
Chimeric Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHMMF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Chimeric Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics (CHMMF) has a Receivables Turnover of 0.00 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #41 out of 840 companies in the Biotechnology industry, placing it in the top 4.9%.
Is Chimeric Therapeutics' Receivables Turnover too high?
Chimeric Therapeutics' current Receivables Turnover is 0.00. Based on the distribution chart, Chimeric Therapeutics ranks #41 out of 840 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #41 out of 840 companies for Receivables Turnover. This places Chimeric Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Receivables Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
